Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction

X
Trial Profile

A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sacubitril/valsartan (Primary)
  • Indications Chronic heart failure; Heart failure
  • Focus Biomarker; Therapeutic Use
  • Acronyms PROVE-HF
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 01 Dec 2022 Results published in the Journal of Cardiac Failure
    • 03 Nov 2022 Results assessing the changes in B-type natriuretic peptide following neprilysin inhibition as measured by 3 immunoassays that recognize different epitopes, published in the Clinical Chemistry.
    • 31 Aug 2022 According to a The Heart Failure Society of America media release, results from this trial will be presented at the The Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM), which will take place September 30 - October 3, 2022.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top